Related Experiment Video

Updated: Jan 24, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

367

A Career in Lung Cancer: Pushing Beyond Chemotherapy

Pradnya Dinkar Patil1, Frances Shepherd2, David H Johnson3

  • 11 Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 18, 2019
PubMed

Insights

Recent advances in non-small cell lung cancer (NSCLC) treatments include targeted therapies and immunotherapies. Overcoming resistance to these vital treatments remains a critical challenge for improving patient survival.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) treatment has significantly advanced.
  • Targeted therapies and immunotherapies have improved survival for NSCLC patients.
  • Resistance to these treatments is a major clinical challenge.

Purpose of the Study:

  • To review therapeutic advances in NSCLC treatment.
  • To discuss mechanisms of resistance to targeted therapies and immunotherapies.
  • To explore strategies for overcoming treatment resistance in NSCLC.

Main Methods:

  • Literature review of therapeutic advances in NSCLC.
  • Analysis of resistance mechanisms to targeted agents and immune checkpoint inhibitors.
  • Synthesis of potential strategies to overcome resistance.

Main Results:

  • Targeted therapies offer survival benefits for oncogene-driven NSCLC.
  • Immune checkpoint inhibitors provide durable responses and improved survival in advanced NSCLC.
  • Primary and acquired resistance limit the efficacy of current therapies.

Conclusions:

  • Despite progress, resistance to NSCLC therapies is a significant hurdle.
  • Understanding resistance mechanisms is key to developing new treatment strategies.
  • Overcoming resistance is crucial for further improving outcomes in non-small cell lung cancer.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Instillation and Fixation Methods Useful in Mouse Lung Cancer Research06:57

Instillation and Fixation Methods Useful in Mouse Lung Cancer Research

Published on: August 31, 2015

29.5K

Related Concept Videos

Drive-Reduction Theory: Push Theory of Motivation01:27

Drive-Reduction Theory: Push Theory of Motivation

Clark Hull's drive-reduction theory, introduced in the 1940s and 1950s and often termed the "push theory" of motivation, provides a framework for understanding how biological and learned drives influence behavior. Hull suggested that motivation originates from the need to alleviate physiological tension caused by unmet biological necessities. The theory proposes that when a basic need, such as hunger or sleep, goes unfulfilled, it creates an internal imbalance. This imbalance, or...
1.2K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
716
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
835
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
626
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
610